Cargando…

Experience With Nintedanib in Severe Pulmonary Fibrosis Associated With Systemic Sclerosis: A Case Series

Detalles Bibliográficos
Autores principales:	Bordas-Martinez, Jaume, Llanos-González, Ana Belén, Jodar-Masanes, Ramon, Vicens-Zygmunt, Vanesa, Bermudo, Guadalupe, Luburich, Patricio, Dorca, Jordi, Molina-Molina, Maria, Suarez-Cuartin, Guillermo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Scientific Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10369530/ https://www.ncbi.nlm.nih.gov/pubmed/37497357 http://dx.doi.org/10.1016/j.opresp.2020.100080

Ejemplares similares

Effects of Early Physical Therapy and Follow-Up in Acute Severe Coronavirus Disease 2019 Pneumonia: A Retrospective Observational Study
por: Bordas-Martínez, Jaume, et al.
Publicado: (2022)

Idiopathic pulmonary fibrosis cluster analysis highlights diagnostic delay and cardiovascular comorbidity association with outcome
por: Bordas-Martínez, Jaume, et al.
Publicado: (2021)

Radio-Histological Correlation of Lung Features in Severe COVID-19 Through CT-Scan and Lung Ultrasound Evaluation
por: Trias-Sabrià, Pere, et al.
Publicado: (2022)

Increased AGE-RAGE ratio in idiopathic pulmonary fibrosis
por: Machahua, Carlos, et al.
Publicado: (2016)

Anti-fibrotic effects of pirfenidone and rapamycin in primary IPF fibroblasts and human alveolar epithelial cells
por: Molina-Molina, M., et al.
Publicado: (2018)

Organizing pneumonia in a patient with hodgkin’s lymphoma and large B cell lymphoma: a rare association
por: Bordas-Martinez, Jaume, et al.
Publicado: (2020)

Lung fibrotic tenascin-C upregulation is associated with other extracellular matrix proteins and induced by TGFβ1
por: Estany, Susanna, et al.
Publicado: (2014)

Gastrointestinal pirfenidone adverse events in idiopathic pulmonary fibrosis depending on diet: the MADIET clinical trial
por: Molina-Molina, Maria, et al.
Publicado: (2023)

Assessing quality of life of idiopathic pulmonary fibrosis patients: the INSTAGE study
por: Suarez-Cuartin, Guillermo, et al.
Publicado: (2019)

Clinical implications of ANCA positivity in idiopathic pulmonary fibrosis patients
por: Suarez-Cuartin, Guillermo, et al.
Publicado: (2020)

A prospective study of lung disease in a cohort of early rheumatoid arthritis patients
por: Robles-Pérez, A., et al.
Publicado: (2020)

Fibroblast viability and phenotypic changes within glycated stiffened three-dimensional collagen matrices
por: Vicens-Zygmunt, Vanesa, et al.
Publicado: (2015)

Erratum to: Fibroblast viability and phenotypic changes within glycated stiffened three-dimensional collagen matrices
por: Vicens-Zygmunt, Vanesa, et al.
Publicado: (2015)

[Translated article] Multiple Solid Nodules at Post-COVID-19 Follow-Up After Mild Pneumonia
por: Bordas-Martinez, Jaume, et al.
Publicado: (2022)

Múltiples nódulos sólidos en el seguimiento post-COVID-19 tras neumonía leve
por: Bordas-Martinez, Jaume, et al.
Publicado: (2022)

Lung Transplant Improves Survival and Quality of Life Regardless of Telomere Dysfunction
por: Planas-Cerezales, Lurdes, et al.
Publicado: (2021)

The adoption of nintedanib in systemic sclerosis: the SENSCIS study
por: Bruni, Teresa, et al.
Publicado: (2020)

Clinical Outcomes of Severe COVID-19 Patients Admitted to an Intermediate Respiratory Care Unit
por: Suarez-Cuartin, Guillermo, et al.
Publicado: (2021)

Serum AGE/RAGEs as potential biomarker in idiopathic pulmonary fibrosis
por: Machahua, Carlos, et al.
Publicado: (2018)

Identification of MMP28 as a biomarker for the differential diagnosis of idiopathic pulmonary fibrosis
por: Maldonado, Mariel, et al.
Publicado: (2018)

Predictors and changes of physical activity in idiopathic pulmonary fibrosis
por: Badenes-Bonet, Diana, et al.
Publicado: (2022)

One‐year clinical experience on the use of Nintedanib in systemic sclerosis
por: Magnani, Luca, et al.
Publicado: (2023)

The relationship between the parenteral dose of fish oil supplementation and the variation of liver function tests in hospitalized adult patients
por: Badia-Tahull, Maria B., et al.
Publicado: (2015)

Chylothorax, in the Spotlight of Lymphangioleiomyomatosis
por: Gámez-Baeza, Pablo, et al.
Publicado: (2022)

Nintedanib downregulates the transition of cultured systemic sclerosis fibrocytes into myofibroblasts and their pro-fibrotic activity
por: Cutolo, Maurizio, et al.
Publicado: (2021)

Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib
por: Wind, Sven, et al.
Publicado: (2019)

Bullous pemphigoid associated with nintedanib
por: Hasson, Amelia M., et al.
Publicado: (2019)

Training load comparison between small, medium, and large-sided games in professional football
por: Beato, Marco, et al.
Publicado: (2023)

Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the randomized controlled INBUILD trial
por: Cottin, Vincent, et al.
Publicado: (2022)

Analysis of pancreatic function in pediatric patients with COVID-19
por: Molina Gutiérrez, Miguel Ángel, et al.
Publicado: (2022)

Spontaneous pneumothorax during nintedanib therapy in patients with systemic sclerosis‐associated interstitial lung disease
por: Sumi, Toshiyuki, et al.
Publicado: (2021)

Correction: Nintedanib downregulates the transition of cultured systemic sclerosis fibrocytes into myofibroblasts and their pro-fibrotic activity
por: Cutolo, Maurizio, et al.
Publicado: (2023)

Nintedanib Reduces Muscle Fibrosis and Improves Muscle Function of the Alpha-Sarcoglycan-Deficient Mice
por: Alonso-Pérez, Jorge, et al.
Publicado: (2022)

Focus on Nintedanib in NSCLC and Other Tumors
por: Manzo, Anna, et al.
Publicado: (2016)

Pharmacokinetics of Nintedanib in Subjects With Hepatic Impairment
por: Marzin, Kristell, et al.
Publicado: (2017)

Nintedanib ameliorates animal model of dermatitis
por: Heo, Min-Jeong, et al.
Publicado: (2020)

Nintedanib-Induced Renal Thrombotic Microangiopathy
por: Fujita, Takeshi, et al.
Publicado: (2021)

Nintedanib in idiopathic and secondary pleuroparenchymal fibroelastosis
por: Nasser, Mouhamad, et al.
Publicado: (2021)

Systemic Sclerosis Associated Interstitial Lung Disease and Nintedanib: A Rare Disease and a Promising Drug
por: Kafle, Sunam, et al.
Publicado: (2021)

Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from SENSCIS-ON
por: Allanore, Yannick, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4o4h9mt8a5oabd6s99rkubl4pj